State of the Art in Clinical Evaluation: What It Means and How to Use It

"State of the art" is one of those regulatory phrases that appears throughout EU MDR without a precise definition — and that ambiguity is where teams get tripped up. It shows up in the General Safety and Performance Requirements (GSPR 1 in Annex I) and in the clinical evaluation requirements, and in both places it carries real weight. Understanding what it actually means in practice, and how to document it properly, is part of building a defensible CER.

What state of the art means in MDR

In the MDR context, "state of the art" doesn't mean "the most advanced technology available." It means the generally acknowledged current best practice for treating or diagnosing the condition your device is intended for — the benchmark against which your device's benefit-risk balance is assessed.

The key MDCG guidance on this is MDCG 2020-5, which describes state of the art as "the developed stage of technical capability at a given time as regards products, processes and services, based on the relevant consolidated findings of science, technology and experience." The practical implication: you have to show that your device's benefit-risk profile is acceptable relative to what clinicians currently do to treat the same condition.

For a novel surgical implant, the state of the art might be the established surgical technique it replaces. For a diagnostic device, it might be the current gold-standard diagnostic pathway. For a device addressing an unmet need with no direct comparator, defining state of the art is harder — but it still must be done.

Why it matters for benefit-risk

The benefit-risk analysis in your CER has to be grounded in the state of the art. A benefit-risk ratio that looks good in isolation may not look good compared to what already exists. If your device is less effective than the current standard of care but also less invasive, you need to document that trade-off explicitly — including the evidence base for both claims. If your device addresses a population with no existing treatment, you need to document that, and explain why the absence of alternatives changes the risk tolerance.

The most common CER weakness here is a benefit-risk section that describes the device's benefits and risks without ever comparing them to anything. That comparison — to the state of the art — is what gives the analysis meaning. Notified Bodies look for this comparison explicitly, because it's what determines whether the benefit-risk is "acceptable" in the regulatory sense.

Documenting the state of the art

State of the art documentation in your CER typically includes a summary of current clinical practice — what clinicians do today to treat or diagnose the condition your device addresses. This is drawn from published clinical guidelines, systematic reviews, consensus statements, and relevant published literature. It's distinct from the literature on your specific device; it's the literature on the condition and how it's currently managed.

Practical steps for documenting it:

1. Identify the relevant clinical practice guidelines for your intended use (from professional societies, NICE, AWMF, ACC/AHA, or equivalent depending on market)
2. Summarise the current standard of care — what are the established treatment or diagnostic options, what are their known benefits and limitations?
3. Position your device relative to those options — what does it add, replace, or improve on?
4. If your device is for an indication with limited or no treatment options, document that clinical unmet need and its scale

This section should be specific to your device's indication. A generic statement that "current treatment options have limitations" does not constitute a state of the art analysis.

When the state of the art changes

The state of the art is not static. Clinical guidelines update, new treatments enter the market, and what was acceptable five years ago may no longer be the benchmark. This is one of the reasons PMCF is important: if a competing technology demonstrates significantly better outcomes after your device is on the market, the state of the art may shift, and your benefit-risk analysis needs to remain valid against the new benchmark.

If your CER's state of the art section references guidelines that have since been updated, that's a gap. Your literature surveillance should include watching for updates to the relevant clinical guidelines for your indication — this is part of what "keeping the CER current" means in practice.

Higher-risk devices and state of the art scrutiny

For Class IIb and Class III devices, Notified Bodies pay close attention to state of the art analysis. The scrutiny is higher because the stakes are higher — the acceptable benefit-risk threshold is more demanding, and the comparison to alternatives must be more thoroughly evidenced. If you are in Class III and your state of the art section is two paragraphs without specific references to comparative clinical data, expect a major finding.